According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

中文翻译：

---

Ninerafaxstat 对非梗阻性肥厚型心肌病的益处

根据 IMPROVE-HCM 试验的数据，有症状的非梗阻性肥厚型心肌病患者对 ninerafaxstat 的耐受性良好，并可改善症状最受限的患者的运动表现。